Hangzhou Tigermed Consulting Co., Ltd. (HNGZY)
USD 4.14
(0.0%)
USD 4.14
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 471.86 Million USD | 20.62% |
| 2022 | 391.21 Million USD | 134.47% |
| 2021 | 166.85 Million USD | 140.11% |
| 2020 | 69.48 Million USD | -60.65% |
| 2019 | 176.58 Million USD | -76.72% |
| 2018 | 758.45 Million CNY | 127.82% |
| 2017 | 332.92 Million CNY | 67.19% |
| 2016 | 199.12 Million CNY | -27.41% |
| 2015 | 274.3 Million CNY | -0.65% |
| 2014 | 276.08 Million CNY | 0.0% |
| 2013 | - CNY | 0.0% |
| 2012 | - CNY | 0.0% |
| 2011 | - CNY | 0.0% |
| 2010 | - CNY | 0.0% |
| 2009 | - CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 3.64 Billion CNY | 9.09% |
| 2024 Q3 | 3.4 Billion CNY | -5.43% |
| 2024 Q2 | 4.07 Billion CNY | 11.56% |
| 2023 Q4 | 3.39 Billion CNY | -7.98% |
| 2023 Q3 | 3.68 Billion CNY | 11.21% |
| 2023 FY | 471.86 Million USD | 20.62% |
| 2023 Q1 | 442.63 Million USD | 12.17% |
| 2023 Q2 | 3.31 Billion CNY | 648.55% |
| 2022 Q3 | 404.28 Million USD | -83.19% |
| 2022 Q4 | 394.62 Million USD | -2.39% |
| 2022 FY | 391.21 Million USD | 134.47% |
| 2022 Q1 | 1.8 Billion CNY | 69.31% |
| 2022 Q2 | 2.4 Billion CNY | 33.59% |
| 2021 Q4 | 1.06 Billion CNY | 11.72% |
| 2021 FY | 166.85 Million USD | 140.11% |
| 2021 Q1 | 84.33 Million CNY | -78.09% |
| 2021 Q2 | 70.16 Million CNY | -16.8% |
| 2021 Q3 | 951.82 Million CNY | 1256.46% |
| 2020 Q2 | 1.67 Billion CNY | 20.03% |
| 2020 Q3 | 294.12 Million CNY | -82.49% |
| 2020 Q4 | 384.94 Million CNY | 30.88% |
| 2020 FY | 69.48 Million USD | -60.65% |
| 2020 Q1 | 1.39 Billion CNY | 28.74% |
| 2019 Q3 | 662.67 Million CNY | -26.65% |
| 2019 Q2 | 903.49 Million CNY | 24.43% |
| 2019 Q4 | 1.08 Billion CNY | 64.04% |
| 2019 Q1 | 726.09 Million CNY | -4.27% |
| 2019 FY | 176.58 Million USD | -76.72% |
| 2018 Q1 | 502.12 Million CNY | 50.82% |
| 2018 Q3 | 365.82 Million CNY | -11.25% |
| 2018 Q2 | 412.19 Million CNY | -17.91% |
| 2018 Q4 | 758.45 Million CNY | 107.33% |
| 2018 FY | 758.45 Million CNY | 127.82% |
| 2017 Q3 | 299.15 Million CNY | 39.27% |
| 2017 Q1 | 144.34 Million CNY | -27.51% |
| 2017 FY | 332.92 Million CNY | 67.19% |
| 2017 Q4 | 332.92 Million CNY | 11.29% |
| 2017 Q2 | 214.79 Million CNY | 48.81% |
| 2016 Q3 | 163.3 Million CNY | -24.98% |
| 2016 FY | 199.12 Million CNY | -27.41% |
| 2016 Q4 | 199.12 Million CNY | 21.94% |
| 2016 Q2 | 217.68 Million CNY | -19.5% |
| 2016 Q1 | 270.42 Million CNY | -1.41% |
| 2015 FY | 274.3 Million CNY | -0.65% |
| 2015 Q3 | 188.04 Million CNY | 883.15% |
| 2015 Q4 | 274.3 Million CNY | 45.87% |
| 2015 Q2 | 19.12 Million CNY | 179.33% |
| 2015 Q1 | 6.84 Million CNY | -97.52% |
| 2014 Q2 | 49.25 Million CNY | 0.09% |
| 2014 FY | 276.08 Million CNY | 0.0% |
| 2014 Q1 | 49.2 Million CNY | 0.0% |
| 2014 Q4 | 276.08 Million CNY | 0.88% |
| 2014 Q3 | 273.66 Million CNY | 455.64% |
| 2013 Q3 | - CNY | 0.0% |
| 2013 Q4 | - CNY | 0.0% |
| 2013 FY | - CNY | 0.0% |
| 2013 Q1 | - CNY | 0.0% |
| 2013 Q2 | - CNY | 0.0% |
| 2012 Q3 | - CNY | 0.0% |
| 2012 FY | - CNY | 0.0% |
| 2012 Q2 | - CNY | 0.0% |
| 2012 Q4 | - CNY | 0.0% |
| 2011 Q4 | - CNY | 0.0% |
| 2011 FY | - CNY | 0.0% |
| 2010 FY | - CNY | 0.0% |
| 2009 FY | - CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| American Bio Medica Corporation | 2.24 Million USD | -20965.565% |
| Arrayit Corporation | 1.07 Million USD | -43665.823% |
| Atlantic International Corp. | 2.93 Million USD | -16002.056% |
| Biocept, Inc. | 12.1 Million USD | -3796.842% |
| Bioqual, Inc. | 3.58 Million USD | -13055.022% |
| CardioGenics Holdings Inc | 72.61 Thousand USD | -649731.515% |
| DermTech, Inc. | 54.39 Million USD | -767.501% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| HTG Molecular Diagnostics, Inc. | 4.83 Million USD | -9661.558% |
| iMD Companies, Inc. | 1.12 Million USD | -42025.526% |
| IDenta Corp. | 789.14 Thousand USD | -59694.849% |
| Interpace Biosciences, Inc. | 11.19 Million USD | -4116.125% |
| Integrative Health Technologies, Inc. | - USD | -Infinity% |
| InVitro International | 43.84 Thousand USD | -1076119.993% |
| Lumos Diagnostics Holdings Limited | 8.04 Million USD | -5765.428% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 3.82 Million USD | -12233.566% |
| NovelStem International Corp. | 3.57 Million USD | -13100.604% |
| Optigenex Inc. | 8.94 Million USD | -5177.738% |
| PharmChem, Inc. | 77.35 Thousand USD | -609919.852% |
| Proteome Sciences plc | 17.15 Million USD | -2650.831% |
| Response Genetics, Inc | 6.37 Million USD | -7304.184% |
| Rennova Health, Inc. | 15.32 Million USD | -2978.205% |
| RushNet, Inc. | 4.82 Million USD | -9683.514% |
| ScreenPro Security Inc. | 207.03 Thousand USD | -227818.437% |
| Stella Diagnostics Inc. | 6.2 Million USD | -7509.944% |
| StageZero Life Sciences Ltd. | 1.8 Million USD | -26113.717% |
| Todos Medical Ltd. | 38.34 Million USD | -1130.491% |